Metrics as of 10/14/2026, 08:01 AM (Berlin time), refresh in progress.
Korro Bio Stock
Korro Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ram Aiyar
- Employees
- 57
- Market cap
- $125 M
- IPO
- 03/10/2019
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread…
Korro Bio stock: price history
1D
-6.0%
1W
-9.7%
1M
-36.2%
6M
-36.8%
YTD
+10.0%
1Y
-80.7%
2Y
-77.2%
5Y
-97.4%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~72% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Korro Bio
Analyst assessment of Korro Bio
PRICE TARGET LOW
US$15.00
CONSENSUS
US$15.00
MEDIAN
US$15.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 06/10/2026
Korro Bio stock metrics
P/E
-0.88
P/B
1.5
EV/EBITDA
-1.46
RETURN ON EQUITY
-18.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.41
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
64.7%
FLOAT SHARES
6,436,719
AVG. DAILY VOLUME (30D)
184,147
Insider transactions (SEC)
FORMELA JEAN FRANCOIS
FORMELA JEAN FRANCOIS
FORMELA JEAN FRANCOIS
FORMELA JEAN FRANCOIS
Dolan Oliver
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Korro Bio stock
What does Korro Bio do?
Korro Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ram Aiyar, the company employs around 57 people.
The IPO was on 03/10/2019; the stock trades on NASDAQ under the ticker KRRO.
What do analysts say about Korro Bio stock?
12 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$15.00, ranging from US$15.00 to US$15.00, with a median of US$15.00.
This is an external assessment, not a statement by Market Jury.
When does Korro Bio report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 72% stronger than usual.
Does Korro Bio pay a dividend?
No, Korro Bio currently does not pay a dividend.
Which stocks are comparable to Korro Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Korro Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Korro Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.